Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study
will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to
placebo in subjects with PAH. Study drug will be administered alone, or on the background of
stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week
placebo-controlled treatment period, and a long-term, blinded extension period.